Ensign Peak Advisors Inc Takes $1.91 Million Position in CG Oncology, Inc. (NASDAQ:CGON)

Ensign Peak Advisors Inc acquired a new position in shares of CG Oncology, Inc. (NASDAQ:CGON) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 60,565 shares of the company’s stock, valued at approximately $1,912,000. Ensign Peak Advisors Inc owned 0.09% of CG Oncology as of its most recent filing with the SEC.

Other hedge funds have also recently made changes to their positions in the company. Ameritas Investment Partners Inc. acquired a new position in CG Oncology during the first quarter worth $102,000. California State Teachers Retirement System acquired a new position in CG Oncology during the 1st quarter worth about $103,000. Rhumbline Advisers boosted its holdings in CG Oncology by 13.0% during the 2nd quarter. Rhumbline Advisers now owns 34,229 shares of the company’s stock valued at $1,081,000 after acquiring an additional 3,940 shares during the period. Massachusetts Financial Services Co. MA grew its position in CG Oncology by 2.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 266,787 shares of the company’s stock valued at $8,422,000 after acquiring an additional 6,899 shares in the last quarter. Finally, BNP Paribas Financial Markets purchased a new stake in CG Oncology during the first quarter worth about $492,000. Hedge funds and other institutional investors own 26.56% of the company’s stock.

CG Oncology Stock Up 3.0 %

CG Oncology stock opened at $37.87 on Friday. The company has a fifty day simple moving average of $35.31 and a 200-day simple moving average of $35.31. CG Oncology, Inc. has a 12-month low of $25.77 and a 12-month high of $50.23.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.14. The business had revenue of $0.11 million for the quarter. On average, equities research analysts expect that CG Oncology, Inc. will post -1.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In other CG Oncology news, Director Hong Fang Song sold 650,455 shares of the stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $35.36, for a total value of $23,000,088.80. Following the transaction, the director now directly owns 586,982 shares in the company, valued at $20,755,683.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $75.00 price objective on shares of CG Oncology in a research note on Tuesday, September 17th. Royal Bank of Canada began coverage on shares of CG Oncology in a research report on Monday, September 23rd. They issued an “outperform” rating and a $66.00 price target for the company. Roth Mkm initiated coverage on CG Oncology in a research report on Tuesday, August 27th. They set a “buy” rating and a $65.00 price objective on the stock. Bank of America started coverage on CG Oncology in a research note on Friday, June 28th. They issued a “buy” rating and a $65.00 price objective on the stock. Finally, Roth Capital raised CG Oncology to a “strong-buy” rating in a research note on Tuesday, August 27th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $64.43.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.